In this review, we discuss the emerging role of STAMP2 in the dysregulation of iron metabolism events leading to NAFLD and suggest therapeutic strategies targeting STAMP2. This evidence concerns the gene STEAP4 and metabolic dysfunction-associated steatotic liver disease.